Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1974 1
1975 3
1978 2
1979 2
1980 1
1981 1
1982 3
1983 3
1984 3
1985 2
1986 3
1987 3
1988 2
1989 1
1990 2
1991 3
1992 2
1993 3
1994 2
1995 3
1996 5
1997 1
1998 2
1999 3
2000 6
2001 12
2002 8
2003 20
2004 12
2005 16
2006 19
2007 13
2008 21
2009 22
2010 15
2011 26
2012 23
2013 17
2014 40
2015 35
2016 30
2017 34
2018 33
2019 41
2020 57
2021 37
Text availability
Article attribute
Article type
Publication date

Search Results

545 results
Results by year
Filters applied: . Clear all
Page 1
An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer.
Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. Feins S, et al. Am J Hematol. 2019 May;94(S1):S3-S9. doi: 10.1002/ajh.25418. Epub 2019 Feb 18. Am J Hematol. 2019. PMID: 30680780 Free article. Review.
Chimeric antigen receptor (CAR) T-cell therapy represents a major advancement in personalized cancer treatment. In this strategy, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen. CAR T cells are then expanded fo …
Chimeric antigen receptor (CAR) T-cell therapy represents a major advancement in personalized cancer treatment. In this strategy, a patient' …
Understanding the tumor immune microenvironment (TIME) for effective therapy.
Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF. Binnewies M, et al. Nat Med. 2018 May;24(5):541-550. doi: 10.1038/s41591-018-0014-x. Epub 2018 Apr 23. Nat Med. 2018. PMID: 29686425 Free PMC article. Review.
It has been possible to identify different subclasses of immune environment that have an influence on tumor initiation and response and therapy; by parsing the unique classes and subclasses of tumor immune microenvironment (TIME) that exist within a patient's tumor, the ab …
It has been possible to identify different subclasses of immune environment that have an influence on tumor initiation and response and ther …
Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.
Abramson JS. Abramson JS. Transfus Med Rev. 2020 Jan;34(1):29-33. doi: 10.1016/j.tmrv.2019.08.003. Epub 2019 Aug 29. Transfus Med Rev. 2020. PMID: 31677848 Review.
Efficacy and safety data for anti-CD19 CAR T-cell therapy in aggressive B-cell lymphomas will be reviewed, as well as novel CAR T-cell designs and strategies for overcoming treatment resistance....
Efficacy and safety data for anti-CD19 CAR T-cell therapy in aggressive B-cell lymphomas will be reviewed, as well as novel CAR T-cel …
Retinoblastoma.
Dimaras H, Corson TW, Cobrinik D, White A, Zhao J, Munier FL, Abramson DH, Shields CL, Chantada GL, Njuguna F, Gallie BL. Dimaras H, et al. Nat Rev Dis Primers. 2015 Aug 27;1:15021. doi: 10.1038/nrdp.2015.21. Nat Rev Dis Primers. 2015. PMID: 27189421 Free PMC article. Review.
Intra-arterial and intravitreal chemotherapy have emerged as promising methods to salvage eyes that with conventional treatment might have been lost. Ongoing international collaborations will replace the multiple different classifications of eye involvement with standardiz …
Intra-arterial and intravitreal chemotherapy have emerged as promising methods to salvage eyes that with conventional treatment might have b …
Mutant p53 on the Path to Metastasis.
Tang Q, Su Z, Gu W, Rustgi AK. Tang Q, et al. Trends Cancer. 2020 Jan;6(1):62-73. doi: 10.1016/j.trecan.2019.11.004. Epub 2019 Dec 16. Trends Cancer. 2020. PMID: 31952783 Free PMC article. Review.
We also discuss the prognostic value of mutant p53 and current status of therapeutic strategies targeting mutant p53. Future studies will shed light on discovering novel mechanisms of mutant p53-driven cancer metastasis and developing innovative therapeutics to improve cli …
We also discuss the prognostic value of mutant p53 and current status of therapeutic strategies targeting mutant p53. Future studies will
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ. Twyman-Saint Victor C, et al. Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9. Nature. 2015. PMID: 25754329 Free PMC article.
Immune checkpoint inhibitors result in impressive clinical responses, but optimal results will require combination with each other and other therapies. This raises fundamental questions about mechanisms of non-redundancy and resistance. ...
Immune checkpoint inhibitors result in impressive clinical responses, but optimal results will require combination with each other an …
Subtyping of triple-negative breast cancer: implications for therapy.
Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Abramson VG, et al. Cancer. 2015 Jan 1;121(1):8-16. doi: 10.1002/cncr.28914. Epub 2014 Jul 16. Cancer. 2015. PMID: 25043972 Free PMC article. Review.
Exploring novel approaches for the treatment of these subtypes is critical, especially because the median survival for women with metastatic TNBC is less than 12 months, and virtually all women with metastatic TNBC ultimately will die of their disease despite systemic ther …
Exploring novel approaches for the treatment of these subtypes is critical, especially because the median survival for women with metastatic …
Gilteritinib: potent targeting of FLT3 mutations in AML.
Levis M, Perl AE. Levis M, et al. Blood Adv. 2020 Mar 24;4(6):1178-1191. doi: 10.1182/bloodadvances.2019000174. Blood Adv. 2020. PMID: 32208491 Free PMC article. Review.
Giltertinib (formerly known as ASP2215) is a novel compound that entered the field late, but moved through the developmental process with remarkable speed. In many ways, this drug's rapid development was facilitated by the large body of knowledge gained over the years from …
Giltertinib (formerly known as ASP2215) is a novel compound that entered the field late, but moved through the developmental process with re …
The Genetic Contribution to Type 1 Diabetes.
Bakay M, Pandey R, Grant SFA, Hakonarson H. Bakay M, et al. Curr Diab Rep. 2019 Nov 4;19(11):116. doi: 10.1007/s11892-019-1235-1. Curr Diab Rep. 2019. PMID: 31686270 Review.
Once we understand the mechanism of action for disease-causing variants, we will be well placed to apply targeted genomic approaches to impede the premature activation of the immune system in an effort to ultimately prevent the onset of T1D....
Once we understand the mechanism of action for disease-causing variants, we will be well placed to apply targeted genomic approaches …
The tumor microenvironment in esophageal cancer.
Lin EW, Karakasheva TA, Hicks PD, Bass AJ, Rustgi AK. Lin EW, et al. Oncogene. 2016 Oct 13;35(41):5337-5349. doi: 10.1038/onc.2016.34. Epub 2016 Feb 29. Oncogene. 2016. PMID: 26923327 Free PMC article. Review.
Further study of how these TME components relate to the different stages of tumor progression in each esophageal cancer subtype will lead to development of novel and specific TME-targeting therapeutic strategies, which offer considerable potential especially in the setting …
Further study of how these TME components relate to the different stages of tumor progression in each esophageal cancer subtype will
545 results